Business Context and Reporting Period
This Form 8-K is a current report filed by Alkermes Plc. on October 15, 2015. The filing addresses a legal dispute regarding the U.S. Food and Drug Administration's (FDA) approval of Alkermes' product ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory and legal developments rather than financial performance.
Material Changes and Events
- FDA Approval: The FDA approved ARISTADA on October 5, 2015, and concurrently denied a Citizen Petition filed by Otsuka Pharmaceutical Development & Commercialization, Inc. ("Otsuka") on July 13, 2015. Otsuka had requested the FDA refuse or delay approval until December 2017.
- Legal Action: On October 15, 2015, Otsuka and its affiliates filed an action for declaratory and injunctive relief in the United States District Court for the District of Columbia against the FDA and the U.S. Department of Health and Human Services. The suit seeks to reverse the FDA's approval of ARISTADA and delay it until December 2017.
- Product Status: Alkermes states that ARISTADA has already been launched.
Outlook, Risks, and Management Commentary
Alkermes management believes Otsuka's legal action is without merit. The company intends to seek court approval to intervene in the matter as a party and will vigorously defend the approval of ARISTADA. The filing includes a caution regarding forward-looking statements, noting that actual results may differ due to uncertainties, including whether the court will deny Alkermes' motion to intervene or grant Otsuka's request for relief.
Key Facts for Investor Verification
- Verify the current status of the lawsuit filed by Otsuka in the U.S. District Court for the District of Columbia.
- Confirm whether Alkermes has successfully intervened in the legal proceedings.
- Monitor any potential court orders that could delay or reverse the FDA approval of ARISTADA.
- Review the impact of this legal uncertainty on the commercial launch and sales projections for ARISTADA.